performed a meta-analysis to evaluate the risk of colitis and diarrhea in patients with advanced melanoma treated with ICIs (anti-PD-1 or anti-CTLA-4 therapy) and concluded that diarrhea and colitis are more frequent in patients treated with CTLA-4 inhibitors (7). Here, CTLA4 is linked to melanoma.